In today's healthcare marketplace, it is growing commonplace to consider patients as customers - and the shoe fits, so to speak. Patients do have choices when it comes to medical care, and now have plenty of ratings and data points to consider when selecting a physician, an outpatient center, a hospital or a long-term care facility. One of those data points is patient experience, which encompasses the many interactions with medical staff, facilities, and representatives. In today's post, we will consider the measurable aspects of the patient experience, including infection control and prevention.
One of the most tracked and reported metrics in today's healthcare facilities is infection rates. Anyone working in a hospital is aware of the importance of keeping these rates as low as possible, as they impact not only patient outcomes, but reimbursement rates and facility reputation as well. It may be an assumption by the general public that these rates are an objective metric with little grey area. However, a recent study investigated what infection prevention experts think about these metrics, and the results may surprise you!
Last week we provided a big-picture overview of the healthcare supply chain, from supplier to patient. This week, we will dig deeper into this process and try to identify places along the supply chain where decisions can impact infection control and prevention. While all hospitals must meet EPA- and FDA-mandated standards for cleanliness and device protocols, there is room for individual choices in how each facility will prepare and respond to pathogens. So where along supply chain are decisions made that influence infection control?
We are fortunate to live in a nation that offers a rich variety of non-profit organizations that support our health and well-being, including groups whose sole focus is to eradicate HAIs. Today's post will explore one of the most important national groups working to end preventable hospital-associated infections, most commonly known as HICPAC.
If you spend any time at all in the world of infection control and prevention, you've run across the NHSN, or National Healthcare Safety Network. Those of us who are not directly involved with infection control, however, may lack a full understanding of what the NHSN truly is. Today's post is for those of us who work on the periphery of infection control efforts: An introduction to the NHSN.
A couple years back, the EOSCU Team had the honor of presenting at the Centers for Disease Control and Prevention (CDC) campus outside of Atlanta, GA. During the meeting with the Division of Healthcare Quality Promotion, we were able to share information about our product as well as data from our first clinical study. This meeting was anything but one-sided, however - the experts at the CDC were able to identify directions and partnerships we should explore in the future. This visit prompted us to present this post about the CDC, and what it does for our nation and the world on a daily basis.
We've covered Candida auris in this blog before. Not only has it been one of the pathogens of concern cited by the Centers for Disease Control and Prevention, this fungus also infected record numbers of inpatients during the COVID-19 pandemic. This disease-causing pathogen has hit headlines once again, this time brining attention to troubling increases in rates and resistance. What can hospitals - and patients - do to avoid this dangerous hospital-associated infection?
In our last post, we explored how adopting a new product can result in some heavy lifting. Not only does product adoption require financial investment, it requires significant investment of time and resources even before the decision is made. Even after the new product is in place, the heavy lifting can continue, especially if the intended users are resistant to change. In today's post, we'll look at the obstacles to adopting new products, even if they are proven to improve patient outcomes or save money. Even if they are considered standard of care.
With World Cancer Day this Saturday, we dedicate this post to those patients facing a cancer diagnosis. As with any serious disease, the many types of cancer put a great deal of stress on the body and can make a person more susceptible to infection. Unique to cancer, however, are the infection risks due to the disease's treatment. Today we will explore how cancer and infection intersect in this special population.
Medical researchers have recently placed more emphasis on the non-medical conditions that impact patient health and outcomes. Collectively known as social determinants of health (SDOH), these are the conditions surrounding birth, growth, living, working, and aging. The distribution of money, power, and resources play heavily into the formula: Those lacking stable access to any (or all) of these factors see impacts on health, including exposure to and infection by disease-causing pathogens. In today's post, we'll explore the intersection of SDOH and infection control and prevention, and describe some of the ways today's health system is trying to address this issue.